Oncology News

The FDA granted orphan drug designation to CT041 for the treatment of adults with relapsed or refractory gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

Although testing for microsatellite instability and mismatch repair deficiency has increased for advanced colorectal cancer, substantial gaps in testing remain among certain patient groups, according to study results.

Deirdre J. Cohen, MD, MS, has been appointed director of the gastrointestinal oncology program at Mount Sinai Health System.

Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.

The addition of nivolumab to first-line chemotherapy significantly improved PFS, but not OS, for patients with advanced or recurrent HER2-negative gastric and gastroesophageal junction cancer, according to phase 3 study findings.

Opioids are a potent pharmacologic option for managing recurrent pain experienced by cancer survivors.

The FDA granted fast track designation to DKN-01 for the treatment of certain patients with gastric cancer or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

The Cleveland Clinic appointed Conor Delaney, MD, PhD, as new CEO and president of Cleveland Clinic Florida region.

Healio Gastroenterology presents the following reports on the most recent research in gastrointestinal cancer.

For patients with familial adenomatous polyposis, incidence of disease progression was not significantly lower with combination eflornithine and sulindac compared with either drug alone, according to recently published results.